News

Enzo Biochem, Inc.: Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results
Enzo Biochem, Inc. (OTCQX: ENZB) ("Enzo" or the "Company") today announced financial results for the fiscal third quarter ended April 30, 2025. Financial ...
MPR35m
FDA Approves Andembry for Prophylactic Use in Hereditary Angioedema
The Food and Drug Administration (FDA) has approved Andembry ® (garadacimab-gxii) for prophylactic use to prevent attacks of hereditary angioedema (HAE) in adult and pediatric pa ...
Zacks Investment Research on MSN23h
ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?
ADMA Biologics ADMA markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain ...
The Manila Times17h
Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results
FARMINGDALE, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (OTCQX: ENZB) ("Enzo” or the "Company”) today ...